Ian Waddell received his PhD in molecular medicine from the University of Dundee (UK). After completing postdoctoral appointments in the US, Ian secured a lectureship at Dundee and spent the next five years expanding his work on diabetes and obesity. He then joined AstroZeneca, taking on roles of increasing responsibility, including Director of Lead Optimization Bioscience and Director of Discovery Medicine in the Oncology iMED. Ian left AZ to take a Head of Biology role with CRUK based in the Drug Discovery Unit at the Christie Hospital, in which he led a biology group across target identification, target validation, screening, and pharmacology (both in vitro and in vivo). He was also responsible for building and managing collaborations with pharma partners and sat on the scientific advisory panel of two early-stage startup biotech companies. Dr. Waddell has a very strong interest in efficient drug discovery and undertook a course at Villanova University that allowed him to become a lean six sigma black belt.